Molecular Reclassification of Diffuse Gliomas: A Feasibility Study of Clinical Features and Survival Outcomes in Colombia
11 affiliations
- 1School of Medicine, Universidad Nacional de Colombia, Bogotá 111321, Colombia
- 2Department of Neurosurgery, Universidad FUCS, Hospital de San José—Sociedad de Cirugía de Bogotá, Bogotá 111411, Colombia
- 3Department of Neurosurgery, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá 110111, Colombia
- 4Department of Pathology, Universidad FUCS, Hospital de San José—Sociedad de Cirugía de Bogotá, Bogotá 111411, Colombia
- 5Group of Basic Sciences in Health, Universidad FUCS, Hospital Infantil Universitario de San José, Bogotá 111221, Colombia
- 6Department of Microbiology, Universidad Nacional de Colombia, Bogotá 111321, Colombia
- 7Department of Neurosurgery, San Fernando Hospital, San Fernando B1646, Buenos Aires, Argentina
- 8School of Medicine, Universidad de Los Andes, Bogotá 111711, Colombia
- 9Dirección Académica, Universidad Nacional de Colombia, Sede de La Paz, La Paz 202010, Colombia
- 10Department of Pathology, Instituto Nacional de Cancerología, Bogotá 111511, Colombia
- 11Research Institute, Universidad FUCS, Hospital de San José—Sociedad de Cirugía de Bogotá, Bogotá 111411, Colombia
Abstract
Background/Objectives: The 2021 World Health Organization Classification of Tumors of the Central Nervous System (WHO CNS5) integrates histological and molecular criteria for adult diffuse gliomas, but comprehensive molecular testing may be difficult to implement in resource-limited settings. This study assessed the feasibility of a sequential, marker-based approach for diagnostic reassessment and described its association with clinical characteristics and overall survival (OS) in adults from Colombia. Methods: We retrospectively analyzed 68 adults with diffuse gliomas treated at two referral hospitals in Bogotá, Colombia, between 2015 and 2023. Molecular assessment used IHC, FISH, PCR, and Sanger sequencing according to the available tissue and diagnostic workflow. The study did not include comprehensive NGS or systematic assessment of combined whole-chromosome 7 gain/chromosome 10 loss (+7/−10). Results: The diagnosis changed after molecular reassessment in 51.5% of cases. The proportion classified as glioblastoma increased from 48.5% under the historical histologic classification to 66.2% under the WHO CNS5-based algorithm, whereas FISH-defined oligodendrogliomas decreased from 17.6% to 11.8%. OS differed among historical histologic groups (p = 0.03), but not among the WHO CNS5-based groups (p = 0.13). Female sex was associated with longer OS in unadjusted analysis (p = 0.02), while age was the only independent predictor in the multivariable analysis. Conclusions: Sequential molecular reassessment materially changed diagnostic categorization in this cohort and was feasible using locally available marker-based methods. However, the results are exploratory, limited by small molecular subgroups, incomplete molecular coverage, and the retrospective treatment context; they should not be interpreted as demonstrating improved treatment selection or survival after reclassification.
Related
- Diffuse brainstem gliomas across the pediatric, adolescent, and adult age spectrum: Clinical and radiological features, molecular profile, and determinants of survival in a multicenter retrospective cohort of 42 patients.
- Clinical features, epidemiology, and survival of patients with core binding factor acute myeloid leukemia in the SEER database
- Transcriptomic FOLFIRINOX sensitivity signatures stratify overall survival and reveal directional reclassification after neoadjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic cancer
- Reclassification of Clinical Familial Hypercholesterolemia Diagnoses After Adjustment of LDL-C for Lipoprotein(a) Cholesterol: A Systematic Review and Meta-Analysis
- Race-neutral GLI-2022 interpretation in GOLD-positive COPD: reclassification in a Jordanian clinical cohort.
BibTeX
@article{ordonezrubiano2026molecular,
title = {{Molecular Reclassification of Diffuse Gliomas: A Feasibility Study of Clinical Features and Survival Outcomes in Colombia}},
author = {Edgar G. Ordóñez-Rubiano and Fabiana Rodríguez and Cristian F. Siabato-Vargas and Luz Dary Gutiérrez-Castañeda and Nicolás Rincón-Arias and Sebastián Espinosa and Alba Cómbita and Matías Baldoncini and Diego F. Gómez-Amarillo and Fernando Hakim and Pedro Andrade-Andrade and César Payán-Gómez and Oscar F. Zorro-Guío and Javier G. Patiño-Gómez and Irene Riveros-Barrera and Oscar Mendoza and Rafael Parra-Medina},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18203364},
url = {https://www.mdpi.com/2072-6694/18/20/3364},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Molecular Reclassification of Diffuse Gliomas: A Feasibility Study of Clinical Features and Survival Outcomes in Colombia
AU - Edgar G. Ordóñez-Rubiano
AU - Fabiana Rodríguez
AU - Cristian F. Siabato-Vargas
AU - Luz Dary Gutiérrez-Castañeda
AU - Nicolás Rincón-Arias
AU - Sebastián Espinosa
AU - Alba Cómbita
AU - Matías Baldoncini
AU - Diego F. Gómez-Amarillo
AU - Fernando Hakim
AU - Pedro Andrade-Andrade
AU - César Payán-Gómez
AU - Oscar F. Zorro-Guío
AU - Javier G. Patiño-Gómez
AU - Irene Riveros-Barrera
AU - Oscar Mendoza
AU - Rafael Parra-Medina
PY - 2026
DA - 2026/10/01
JO - Cancers
DO - 10.3390/cancers18203364
UR - https://www.mdpi.com/2072-6694/18/20/3364
AB - Background/Objectives: The 2021 World Health Organization Classification of Tumors of the Central Nervous System (WHO CNS5) integrates histological and molecular criteria for adult diffuse gliomas, but comprehensive molecular testing may be difficult to implement in resource-limited settings. This study assessed the feasibility of a sequential, marker-based approach for diagnostic reassessment and described its association with clinical characteristics and overall survival (OS) in adults from Colombia. Methods: We retrospectively analyzed 68 adults with diffuse gliomas treated at two referral hospitals in Bogotá, Colombia, between 2015 and 2023. Molecular assessment used IHC, FISH, PCR, and Sanger sequencing according to the available tissue and diagnostic workflow. The study did not include comprehensive NGS or systematic assessment of combined whole-chromosome 7 gain/chromosome 10 loss (+7/−10). Results: The diagnosis changed after molecular reassessment in 51.5% of cases. The proportion classified as glioblastoma increased from 48.5% under the historical histologic classification to 66.2% under the WHO CNS5-based algorithm, whereas FISH-defined oligodendrogliomas decreased from 17.6% to 11.8%. OS differed among historical histologic groups (p = 0.03), but not among the WHO CNS5-based groups (p = 0.13). Female sex was associated with longer OS in unadjusted analysis (p = 0.02), while age was the only independent predictor in the multivariable analysis. Conclusions: Sequential molecular reassessment materially changed diagnostic categorization in this cohort and was feasible using locally available marker-based methods. However, the results are exploratory, limited by small molecular subgroups, incomplete molecular coverage, and the retrospective treatment context; they should not be interpreted as demonstrating improved treatment selection or survival after reclassification.
SN - 2072-6694
ER -